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ABSTRACT 
The recognition that the development of cancer is associated with acquired immunodeficiency, mostly 
against cancer cells themselves, and understanding pathways inducing this immunosuppression, has led to 
a tremendous development of new immunological approaches, both vaccines and drugs, which overcome 
this inhibition. Both “passive” (e.g. strategies relying on the administration of specific T cells) and “active” 
vaccines (e.g. peptide-directed or whole-cell vaccines) have become attractive immunological approaches, 
inducing cell death by targeting tumor-associated antigens. Whereas peptide-targeted vaccines are usually 
directed against a single antigen, whole-cell vaccines (e.g. dendritic cell vaccines) are aimed to induce 
robust responsiveness by targeting several tumor-related antigens simultaneously. The combination of 
vaccines with new immuno-stimulating agents which target “immunosuppressive checkpoints” (anti-CTLA-
4, PD-1, etc.) is likely to improve and maintain immune response induced by vaccination. 
KEY WORDS: Cancer vaccines, dendritic cells, hematological malignancies, immunotherapy  
Dendritic Cell Cancer Vaccines 
 
 
Rambam Maimonides Medical Journal  2  October 2014  Volume 5  Issue 4  e0024 
 
INTRODUCTION 
In  a  large  proportion  of  patients,  hematological 
malignancies remain incurable with conventional 
chemotherapy.  The  most  promising  new  cancer 
treatment  approach is  immunotherapy  that 
harnesses the immune system to fight cancer by 
inducing or suppressing immune responses. 
The earliest evidence for the role of the immune 
response against cancer cells was provided in the 
work by William Coley, who injected Streptococcus 
pyogenes to sarcoma patients in an effort to repro-
duce spontaneous remissions observed in cancer 
patients developing erysipelas. Ten percent of these 
incurable  non-resectable  patients  responded.1 
Similar promising results obtained in several other 
studies led to the use of bacilli Calmette–Guérin 
(BCG) for cancer immunotherapy, which continues 
to be employed to the present day as an effective 
therapy against superficial bladder cancer.2  
The immune system has the ability to identify 
and eliminate tumor cells on the basis of tumor-
specific antigens in the process of “immuno-editing” 
that includes three phases: elimination, equilibrium, 
and escape.3 At the elimination phase,4 tumor cells 
are  efficiently  detected  and  destroyed  by  the 
immune system. Tumor cells not completely elimin-
ated by the immune system proceed to the equilibri-
um phase where the tumor persists but is not ex-
panding. The escape phase begins when the balance 
between the immune response and the tumor moves 
towards tumor growth, which may  be caused by 
immune  exhaustion,  inhibition,  or  occurrence  of 
tumor cell variants that allow the tumor to evade the 
immune system.  
The information regarding immune response to 
cancer  remained  controversial  throughout  the 
twentieth  century;  only  with  the  development  of 
mouse  models  has  our  understanding  advanced 
significantly. For instance, a series of experiments 
demonstrated that mutant mice with severe com-
bined immunodeficiency, lacking T and B lympho-
cytes, had a high tendency to develop lymphomas 
and carcinomas.5 Furthermore, other studies have 
shown that mice injected with irradiated tumor cells 
became protected against lethal viable cells of the 
same tumor.6  
Accordingly, studies in humans reported a high 
incidence of lymphomas and other malignancies in 
immunocompromised states.7,8 Patients undergoing 
solid organ or bone marrow transplantation were 
found to be at an increased risk of developing post-
transplant lymphoproliferative disorders (PTLD),9 
and therefore discontinuation of immunosuppres-
sive drugs potentially resulting in immunity recon-
struction could contribute to successful manage-
ment of these patients.  
One of the earliest and most successful immuno-
therapies developed for hematological malignancies 
was  hematopoietic  stem  cell  transplantation 
(HSCT).  While  this  procedure  is  associated  with 
significant  morbidity  and  mortality,  it  has  been 
shown to prolong long-term disease-free survival as 
well as overall survival and can  be curative in a 
subset of patients. This efficacy of HSCT is attrib-
uted to the graft-versus-disease effect mediated by 
allogeneic donor T cells.10 Another demonstration of 
the impressive immune reaction in the HSCT setting 
is the donor lymphocyte infusion that can eradicate 
post-transplant disease relapse.11  
PRIMARY MECHANISMS OF IMMUNE 
ESCAPE 
Although  the  immune  system  has  a  potential 
capability  to  recognize  and  attack  cancer  cells, 
tumor cells manage to escape immune recognition 
by employing different mechanisms which normally 
protect healthy tissues from autoimmune reactions. 
These  mechanisms  include  inefficient  processing 
and presentation of tumor antigens, up-regulation 
of negative co-stimulatory ligands which mediate T 
cell  anergy,12  expansion  of  regulatory  cells,  and 
production of “immunosuppressive molecules,” such 
as  transforming  growth  factor  β  (TGF-β),13  Fas 
ligand,14  and  the  immunosuppressive  enzyme 
indolamine-2,3-dioxygenase  (IDO).15  Tumor  cells 
can also directly escape T cell recognition through 
down-regulating major histocompatibility complex 
(MHC)  class  I  or  disabling  other  components  of 
antigen process.16  
Inefficient Processing and Presentation of 
Tumor Antigens  
Recognition of tumor-specific antigens is mediated 
by selected MHC molecules. Tumor cells can directly 
escape T cell recognition through down-regulation 
of either MHC class I, or tumor antigen expression. 
Moreover,  cancer-induced  defects  in  human 
leukocyte  antigen  (HLA)  or  in  other  antigen-
processing  molecules,  like  transporter  associated 
with antigen processing (TAP), may also contribute 
to this immune escape. Additionally, cancer cells  
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often  induce  secretion  of  “immunosuppressive” 
factors which interfere with dendritic cell matura-
tion and function, leading to an inefficient T cell 
activation against tumor cells. 
Inhibitory T Cell Pathways  
The  T  cell  receptor  co-stimulatory  pathways  are 
important immune checkpoints involved in main-
taining  homeostasis  of  the  immune  system  by 
regulating T cell activation.  
One  of  the  significant  immune  checkpoint 
receptors  is  cytotoxic  T-lymphocyte  associated 
antigen  4  (CTLA-4)  expressed  on  T  cells  which 
down-regulates  T  cell  activation  aiming  to  limit 
damage to self-tissues.17 The expression of CTLA-4 
on the T cell surface reduces the activation of T cells 
by competing with the T cell co-stimulatory receptor 
CD28  in  binding  to  identical  ligands  CD80  and 
CD86  and  delivering  inhibitory  signals  to  the  T 
cell.18 Upon binding CTLA-4 arrests T cell activation 
by  down-regulation  of  CD4+  T  helper  cells  and 
increase  in  immunosuppressive  activity  of  T 
regulatory cells.  
Tumor cells can exploit this pathway by expres-
sing  ligands  for  the  CTLA-4  receptor  on  their 
surface. Blockade of CTLA-4 with specific mono-
clonal  antibodies  can  shift  the  immune  system 
balance toward T-cell activation, leading to tumor 
rejection. Both retrospective and prospective phase 
II  and  III  studies  have  recently  demonstrated  a 
significant antitumor activity of the anti-CTLA-4 
blocking antibody ipilimumab in advanced melan-
oma.19 The response rate in patients with advanced-
stage disease who failed previous therapies and had 
no  other  potential  therapeutic  opportunities 
approached  40%  and  was  translated  into  an 
improved survival.20,21 Interestingly, response was 
accompanied by increase in lymphocyte count and a 
decrease in regulatory T cells (Tregs).21  
Another  key  checkpoint  pathway  mediating 
tumor-induced  immune  suppression  is  the 
programmed death-1 (PD-1); PD-1 is a cell surface 
inhibitory  receptor  expressed  on  T  cells,  B  cells, 
monocytes,  and  natural  killer  T  cells,  following 
activation.22 It has two ligands: PD-L1 (B7-H1) and 
PD-L2 (B7-DC), both expressed on antigen-present-
ing cells (APCs).23 The ligand PD-L1, thought to be 
the  main  mediator  of  PD-1-dependent  immuno-
suppression, is also expressed on some non-hemato-
poietic cells. The interaction of PD-1 with its ligand 
inhibits T-cell receptor signaling, down-regulates 
the expression of some antiapoptotic molecules, and 
influences the cell cycle.24 The PD-1 pathway is an 
important regulator of induction and maintenance 
of peripheral tolerance involved in preventing tissue 
damage in chronic inflammation.25  
The PD-1 pathway may have a key role in the 
interaction of tumor cells with the host immune re-
sponse, and tumor cell PD-L1 expression may serve 
as a mechanism of adaptive immune resistance. 
The  ligand  PD-L1  has  been  reported  to  be 
expressed on many different tumor cells.24 High PD-
L1 expression, at least in the solid tumor scenario, 
appears to correlate with increased tumor aggres-
siveness and high risk of death.26,27  
Tumor-infiltrating  lymphocytes  (TILs)  from 
patients with cancer, typically expressing PD-1, are 
characterized  with  an  impaired  antitumor  func-
tionality.28  
Blockade  of  either  PD-1  or  its  ligands  with  a 
specific  monoclonal  antibody  enhances  T-cell 
effector function, including cytolytic activity against 
tumor cells. Immune effects of the blockade have 
been shown in a variety of preclinical29 and clinical 
studies in both solid tumors (e.g. melanoma, lung 
cancer, etc.)30 and hematological malignancies.31 A 
recent study, investigating the safety and efficacy of 
anti-PD-1 antibody (Ab) in conjunction with rituxi-
mab in patients with relapsed follicular lymphoma, 
reported  an  encouraging  safety  profile  and  anti-
lymphoma activity, with an overall response rate of 
66%, including 52% complete remissions.31  
Regulatory Immune Cells 
The tumor microenvironment is controlled by Tregs 
and  other  cell  populations  like  myeloid-derived 
suppressor cells (MDSC) that create an immuno-
suppressive  microenvironment  and  suppress 
antitumor effector T cells. Classic regulatory T cells 
are  thymus-derived  CD4+CD25+FOXP3+  T  cells, 
which are responsible for inducing and maintaining 
peripheral tolerance through suppressing immune 
responses.32 Tregs also play a major role in tumor 
surveillance,  suppressing  an  antitumor  response 
both  in  tumor  bed  and  systemically.  Tregs  are 
recruited to tumor sites, where they suppress anti-
tumor cytotoxic responses. As most tumor antigens 
are self-antigens, Treg-mediated suppression has 
been proposed as a potential mechanism explaining 
the  failure  of  antitumor  immunity.  Indeed,  an  
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increased number of Tregs in peripheral blood and 
tumor bed, often reported in both solid and hemato-
oncological  cancers,  is  associated  with  a  worse 
prognosis.33–35  
Depletion  of  Tregs  or  inhibition  of  their 
suppressive activity can enhance tumor immunity. 
This may be achieved using monoclonal antibodies 
(mAb)  specific  for  cell  surface  molecules  (CD25, 
Toll-like receptor, CTLA-4, GITR, OX40, and folate 
receptor 4) that are  predominantly expressed  by 
Tregs or specifically able to modulate Treg func-
tion.33 For instance, removal of Tregs by anti-CD25 
mAb or toxin-conjugated anti-IL-2 (denileukin difi-
tox)  facilitates  the  activation  and  expansion  of 
effector T cells that inhibit tumor growth in rodents. 
Since CD25 expression is also induced in activated 
effector T cells and IL-2 is required for the expan-
sion of CD8+ T cells, treatment with anti-CD25 mAb 
or  denileukin  difitox  may  concurrently  dampen 
effector T-cell responses.36  
Preclinical  data  suggest  Treg  depletion  to 
promote tumor regression.37–39 Development of new 
strategies  aiming  to  attenuate  selectively  Tregs’ 
immunosuppressive  effect  in  the  tumor  micro-
environment is needed.  
As blockade of CTLA-4 is known to abrogate the 
suppressive activity of Tregs and improves tumor 
immunity,  the  combination  of  anti-CTLA-4  mAb 
and anti-GITR mAb elicits a more potent antitumor 
response causing rejection of advanced stage tumors 
than does either mAb alone.  
Another  suppressive  subset  of  cells  is  the 
heterogeneous population of MDSC that are expand-
ed in cancer and have the capacity to suppress the 
immune response; MDSC are generated in the bone 
marrow in response to cancer-derived factors and 
are recruited to the tumor site by CCL2, CXCL12, 
and CXCL5.40 The MDSCs suppress the activation of 
T effector and natural killer cells and induce expan-
sion of Tregs. 
VACCINE THERAPY FOR MYELOMA: 
REVERSING TUMOR-MEDIATED 
IMMUNE SUPPRESSION  
The development of multiple myeloma is associated 
with progressive immune dysregulation that pro-
motes  tumor  growth  and  resistance.41,42  The 
immunologic milieu is characterized by the dimin-
ished activity of antigen-presenting cells and loss of 
effector cell function including deficiencies in T and 
natural  killer  (NK)  cell  function.  Myeloma  cells 
present antigens in the absence of co-stimulation 
and inflammatory signals, resulting in the inactiva-
tion of potentially reactive T cell populations. As 
such, antigens that are aberrantly expressed by the 
myeloma clone are unrecognized.43,44 Investigators 
have  sought  out  strategies  to  reverse  tumor-
mediated immune suppression such that malignant 
cells are designated as foreign by immune-based 
mechanisms and eliminated. One such approach is 
the use of tumor vaccines to present tumor antigens 
effectively in the context of immune-activating sig-
nals. A primary strategy is through the use of potent 
antigen-presenting cells known as dendritic cells 
(DCs)  that  constitutively  express  co-stimulatory 
molecules and inflammatory cytokines necessary for 
the primary activation of immunity. 
Dendritic cells represent a diverse network of 
antigen-presenting cells that play a prominent role 
in  mediating  immune  responsiveness.45,46  Circu-
lating  DC  populations  have  been  identified  as 
myeloid and plasmacytoid in origin, characterized 
by the expression of CD11c and CD123, respectively. 
Myeloid  DCs  exhibit  functional  deficiencies  in 
patients with myeloma that may impact their ability 
to elicit immunologic responses.43 Plasmacytoid DCs 
have  been  identified  as  stromal  elements  in 
myeloma that help to mediate tolerance. In contrast, 
ex vivo-generated DCs from patients with myeloma 
exhibit a functionally active phenotype characterized 
by  expression  of  co-stimulatory  molecules  and 
stimulatory cytokines and may serve as a vehicle for 
tumor vaccines.47,48 Strategies to load tumor anti-
gens  include  pulsing  with  peptides,  proteins,  or 
lysates,  electroporation  with  tumor  onto  DCs 
including the use of whole-tumor cell or antigen-
specific  RNA,  tumor-derived  apoptotic  bodies, 
transduction with  viral vectors expressing tumor 
antigens, and whole-cell fusion between DCs and 
myeloma cells.49–55 
SINGLE ANTIGEN APPROACHES 
Myeloma-associated antigens have been identified 
that serve as potential targets for cellular immuno-
therapy. The idiotype protein represents a myeloma-
specific  antigen  represented  by  the  unique 
immunoglobulin gene arrangement of the malignant 
plasma cell.56–61 Idiotype-based vaccines potentially 
induce a highly selective immune response but are 
potentially  limited  by  uncertain  immunogenicity 
and the challenge of isolating the unique M protein 
of  each  patient.  In  previously  reported  studies,  
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vaccination with the idiotype protein in conjunction 
with GM-CSF or IL-12 was associated with antigen-
specific  T  cell  responses  that  correlated  with 
improved  outcomes.62  Responses  have  also  been 
observed  following  vaccination  with  DCs  pulsed 
with the idiotype protein and exposed to CD40L to 
induce maturation.63,64  
Several shared antigens have been identified in 
myeloma  cells  that  are  uniquely  or  aberrantly 
expressed  and  serve  as  potential  targets  for 
immunotherapy.  These  include  MUC1,  WT1, 
PRAME, CYP1B1, and HSP96.65–69 A peptide-based 
vaccine  for  WT1  administered  with  immune 
adjuvant  has  been  shown  to  elicit  immunologic 
response in patients with hematological malignan-
cies and a decrease in measures of disease.70 In a 
more  recent  study,  WT1-specific  T  cells  were 
detected in patients who had undergone allogeneic 
transplantation and correlated with durable remis-
sion. The cancer testis antigen, NY-ESO, demon-
strates increased expression by plasma cells in the 
setting of advanced disease, creating an appealing 
target for immune-based therapy.71 Repetitive stim-
ulation with DCs pulsed with an NY-ESO-derived 
peptide  elicits  a  strong  cytotoxic  T  lymphocyte 
(CTL) response in vitro, demonstrating an activated 
phenotype capable of lysing primary myeloma cells. 
Several other peptides which are highly expressed 
on  myeloma  cells  and  are  important  in  the 
pathogenesis of the disease have been identified as 
potential  immunogenic  targets.  Heteroclitic  pep-
tides derived from XBP1 (X-box-binding protein 1), 
CD138 (syndecan-1), and CS1 were shown alone or 
in combination to induce the expansion of myeloma-
specific  T  cells  with  the  capacity  to  lyse  tumor 
cells.72–75  A  trial  is  currently  underway  in  which 
patients with smoldering myeloma undergo vaccina-
tion with combined myeloma-associated peptides in 
the context of immune adjuvant.  
WHOLE-CELL APPROACHES 
The use of whole-cell-derived antigens for vaccina-
tion  may  be  advantageous  by  eliciting  a  broad 
polyclonal  response  that  effectively  targets  the 
heterogeneity of the myeloma cell population. In 
one example, DCs pulsed with myeloma cell lysates 
induce myeloma-associated immunity, although the 
clinical  efficacy  was  uncertain.47  Other  strategies 
that have been pursued include the use of whole-cell 
RNA, DNA, or apoptotic bodies for antigen loading 
onto DCs.76,77 
We have developed a vaccine model in which 
patient-derived myeloma cells are fused with auto-
logous  DCs  such  that  a  broad  array  of  myeloma 
antigens are effectively presented in the context of 
enhanced co-stimulation.78–80 In a murine adeno-
carcinoma  model,  vaccination  with  DC/tumor 
fusions protected animals from an otherwise lethal 
challenge of tumor cells. Most significantly, vaccina-
tion  was  able  to  eradicate  established  disease  in 
animals with advanced pulmonary metastases. Simi-
larly, DC/multiple myeloma (MM ) cell fusions were 
effective in a syngeneic murine myeloma model, and 
therapeutic efficacy was further enhanced by co-
administration  of  IL-12.  In  preclinical  human 
studies, fusion of DCs and MM cells elicited the 
expansion of activated T cells that potently lysed 
autologous  myeloma  cells  in  vitro.  We  demon-
strated that cell fusion induces DC maturation as 
manifested by increased expression of co-stimula-
tory molecules and maturation markers.81 Vaccine 
efficacy  was  further  enhanced  by  exposure  to 
inflammatory  signals  such  as  Toll-like  receptor 
agonists.  Sequential  stimulation  of  T  cells  with 
DC/tumor  fusions  and  ligation  of  the  T  cell  co-
stimulatory complex with anti-CD3/CD28 results in 
the dramatic expansion of tumor-specific lympho-
cytes.82 
A phase I clinical trial was completed in which 
successive cohorts of patients with advanced myelo-
ma underwent vaccination with escalating doses of 
autologous DC/MM fusions.83 Patients had under-
gone a median of four prior treatment regimens. 
Dendritic cells were generated from adherent mono-
nuclear cells cultured with GM-CSF and IL-4 and 
matured  with  TNFα.  Autologous  myeloma  cell 
preparations  were  obtained  from  bone  marrow 
aspirates  of  patients  with  at  least  20%  marrow 
involvement with tumor cells. Dendritic cells and 
myeloma cells underwent phenotypic characteriza-
tion to identify markers unique to each population. 
Dendritic cells were subsequently fused with auto-
logous myeloma cells by co-culture in the presence 
of polyethylene glycol. Fusion cells were quantified 
by  determining  the  percentage  of  cells  that 
coexpressed  unique  DC  and  myeloma  antigens. 
Vaccine production was feasible with achievement of 
the planned dose escalation up to a dose of 4 × 106 
fusion cells. Patients underwent serial vaccination in 
conjunction with GM-CSF. Vaccine-associated tox-
icity consisted of transient grade 1–2 vaccine site 
reactions most commonly, while clinically signifi-
cant autoimmunity was not observed. Biopsy of the  
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vaccine bed demonstrated a dense infiltrate of CD8+ 
T cells consistent with T cell expansion occurring at 
the site of vaccination. Vaccination resulted in the 
expansion of myeloma-specific T cells in a majority 
of patients as manifested  by the percent of  CD4 
and/or CD8 T cells expressing IFNγ following ex 
vivo exposure to autologous tumor lysate. Humoral 
responses  directed  against  myeloma-associated 
targets were documented by SEREX analysis. Of 
note,  66%  of  patients  demonstrated  a  period  of 
disease  stability  ranging  from  several  months  to 
greater than 2 years after vaccination. 
VACCINATION IN CONJUNCTION WITH 
AUTOLOGOUS TRANSPLANTATION  
While vaccination induced anti-myeloma immunity 
in patients with advanced disease, we postulated 
that clinical efficacy was more likely in the setting of 
minimal disease in which tumor-mediated disrup-
tion of cellular immunity is less pronounced. 
In animal models, the period of lymphopoietic 
reconstitution is associated with enhanced respons-
iveness to tumor vaccines due to the relative deple-
tion of regulatory T cells and the increased presence 
of tumor reactive clones. Of note, vaccination with 
idiotype pulsed antigen-presenting cells post-trans-
plant was associated with improved progression-free 
survival as compared to a historical control cohort.59 
Based on these studies, we have conducted a phase 
II study in which patients with myeloma underwent 
vaccination  with  DC/MM  fusions  in  conjunction 
with autologous transplant.84 Patients underwent 
vaccine production during the period of pre-trans-
plant induction therapy. A majority of the patients 
underwent  vaccination  following  post-transplant 
hematopoietic recovery, while a small cohort under-
went  pre-transplant  vaccination  with  post-trans-
plant boosting. Vaccination was well tolerated with-
out evidence of clinically significant autoimmunity 
or impact on post-transplant engraftment. While 
general  measures  of  cellular  immunity  were  de-
pressed following transplant, a paradoxical increase 
in myeloma-specific T cells was observed that was 
further boosted following vaccination. In the cohort 
of patients undergoing post-transplant vaccination 
alone, 29% of patients achieved complete remission 
within  the  first  100  days  following  transplant. 
Following vaccination, between day 100 and 1 year 
post-transplant, 54% achieved complete remission, 
suggesting that the induction of myeloma-specific 
immunity was associated with the targeting of post-
transplant minimal residual disease. 
IMMUNOMODULATORY THERAPY AND 
VACCINATION 
Immunomodulatory agents such as lenalidomide 
and pomalidomide have demonstrated significant 
efficacy in patients with myeloma through a variety 
of mechanisms, including direct cytotoxicity, inhibi-
tion  of  stromal  myeloma  cell  interactions,  and 
impact  on  anti-myeloma  immunity.85,86  As  these 
agents  are  thought  to  enhance  the  immunologic 
environment  in  patients  with  myeloma,  there  is 
considerable interest in combining these agents with 
tumor vaccines. Lenalidomide has been shown to 
augment NK cell function.87 We demonstrated that 
lenalidomide decreases PD-1 expression by T cells 
and polarizes T cell towards a Th1 as compared to a 
Th2  phenotype  after  stimulation  with  DC/tumor 
fusions.88 Previous studies have demonstrated that 
lenalidomide enhances response to the Pneumovax 
vaccine.89 Based on these findings, a multicenter 
phase II randomized trial is being initiated by the 
Clinical Trials Network Cooperative group in which 
patients will receive post-transplant lenalidomide 
maintenance  alone  or  in  conjunction  with  serial 
vaccination with DC/myeloma fusions.  
The negative co-stimulatory molecules CTLA-4 
and PD-L1/PD-1 are critical mediators of tumor-
mediated immune suppression and tolerance, and 
antibodies that block their function have become a 
major new area of cancer therapeutics.22,90 Blockade 
of CTLA-4 has demonstrated activity via activation 
of  cell-mediated  immunity  and  has  received 
approval  by the FDA  for  patients  with recurrent 
melanoma. Blockade of PD-1 has been shown to 
induce  durable  disease  regression  in  a  subset  of 
patients with melanoma and renal and non-small 
lung  cancer,  and  is  currently  being  studied  in 
patients  with  hematological  malignancies.  In  a 
phase II trial, patients with recurrent lymphoma 
underwent  serial  infusions  with  PD-1  antibody 
following autologous transplantation. Investigators 
are now examining the potential synergy between 
checkpoint blockade and vaccine therapy.  
We have demonstrated that PD-L1 is strongly 
expressed by human myeloma cell lines as well as 
patient-derived  samples.  Increased  expression  of 
PD-1 is seen on circulating T cells in patients with 
active disease. We have shown that PD-1 blockade 
augments the efficacy of the DC/MM fusion vaccine 
in vitro as manifested by increased T cell expression 
of IFNγ, decreased expansion of regulatory T cells, 
and enhanced lysis of myeloma targets.91 Based on  
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these  findings,  a  clinical  trial  is  now  underway 
examining the efficacy of a PD-1 antibody  alone or 
in  conjunction  with  the  DC/MM  fusion  vaccine 
following autologous transplantation. Preliminary 
results  have  demonstrated  that  post-transplant 
treatment  with  PD-1  antibody  resulted  in  the 
expansion of myeloma-specific T cells and antigen-
specific responses against MUC1, WT1, PRAME, NY-
ESO,  and  survivin  in  the  bone  marrow  and 
peripheral blood.92  
DENDRITIC CELL/TUMOR FUSION 
VACCINATION FOR PATIENTS WITH 
ACUTE MYELOID LEUKEMIA  
Given the findings in myeloma, we have explored 
the  potential  role  of  fusion  cell  vaccination  in 
patients with acute myeloid leukemia. The potential 
role of cellular immunotherapy in targeting acute 
myeloid leukemia cells is highlighted by the observa-
tion that a subset of patients are rendered disease-
free following allogeneic transplantation due to the 
graft-versus-leukemia effect mediated by alloreac-
tive T cells. We are conducting a  clinical trial in 
which patients with active disease undergo collec-
tion of leukemia cells. Those patients who achieve 
remission subsequently undergo vaccine generation 
and  serial  vaccination.  In  preliminary  findings, 
vaccination was associated with the induction of 
leukemia-specific immunity as manifested by the 
expansion of tumor-reactive lymphocytes and leu-
kemia antigen-specific T cells. In the initial cohort of 
treated patients with a median age of 66, 70% have 
remained in remission with a mean follow-up of 3 
years. 
In conclusion, tumors frequently interfere with 
the development and function of immune responses. 
Cancer  immunotherapy  aims  to  employ  the 
power and specificity of the immune system for the 
treatment of malignancy. Studies exploring immune 
combinations are ongoing, and new immunological 
approaches are under development. 
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